GABELLI FUNDS LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 2.78 and the average weighting 0.2%.

Quarter-by-quarter ownership
GABELLI FUNDS LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$3,314,952
+1600.0%
178,800
+1177.1%
0.03%
+1250.0%
Q3 2022$195,000
+1.0%
14,0000.0%0.00%
+100.0%
Q2 2022$193,000
-15.4%
14,0000.0%0.00%0.0%
Q1 2022$228,0000.0%14,0000.0%0.00%0.0%
Q4 2021$228,000
-26.9%
14,000
-33.3%
0.00%
-50.0%
Q3 2021$312,000
-25.5%
21,0000.0%0.00%
-33.3%
Q2 2021$419,000
-13.6%
21,0000.0%0.00%0.0%
Q1 2021$485,00021,0000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders